Skip to main content

Advertisement

Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Nuclear heterogeneous nuclear ribonucleoprotein D is associated with poor prognosis and interactome analysis reveals its novel binding partners in oral cancer

Fig. 5

Evaluation of hnRNPD overexpression as a prognostic marker for OSCC. a Evaluation of nuclear hnRNPD as a prognostic marker. Based on sensitivity and specificity values a cut-off ≥4 was defined as positive criterion for hnRNPD (nuclear). Kaplan–Meier estimation of recurrence-free survival (RFS; no recurrence/metastasis) in OSCC patients showing nuclear immunostaining of hnRNPD was 15 months as compared to 69 months for the patients showing low scores for nuclear hnRNPD immunostaining (p = 0.013). b Kaplan–Meier estimation of recurrence-free survival, in node negative OSCC patients showing nuclear immunostaining of hnRNPD was median RFS = 22 months as compared to 69 months for the patients showing low scores for nuclear hnRNPD immunostaining and absence of node (p = 0.028). c Evaluation of nuclear hnRNPD as a diagnostic marker for distinguishing oral dysplasia and OSCCs from normal oral tissues. Panel shows ROC analysis for i Oral dysplasia vs. normal and ii OSCCs vs. normal oral tissues

Back to article page